Signal from the log
KymaThera
80 M$ · Series B · United States
KymaThera développe K-1728, un comprimé qui bloque les formes mutées de l'enzyme PI3Kα sans toucher la forme normale, dont l'inhibition provoque l'hyperglycémie des traitements actuels. Cibles visées : cancer du sein HR+/HER2- et malformations vasculaires ; Alta Partners mène cette série B avant une première phase 1.
Verified
Announced on , logged by the watch of 6 October 2026.
- Operation
- Funding round
- Announced amount
- 80 M$
- Stage
- Series B
- Country
- United States
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Alta Partners , with J. Wood Capital
Provenance
Source endpoints,prnewswire
Logged on 6 October 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.